OBJECTIVE: The evidence for the efficacy of D-cycloserine (DCS) for augmenting cognitive behavioral therapy (CBT) for anxiety disorders has been mixed. Guided by preclinical research and initial findings from a small-scale study involving humans, we tested the hypothesis that DCS enhancement of exposure therapy would be specific to successful exposure sessions. METHOD: Medication-free adults with generalized social anxiety disorder (N = 145) received 50 mg of DCS or placebo 1 h before each of 5 exposure sessions that were part of a standardized 12-session group CBT protocol. Participants provided fear ratings at the beginning and just before the end of exposure exercises. Independent raters, blind to group assignment, administered the clinical global impression improvement and severity scales at each session and at posttreatment. RESULTS: Mixed-effects analyses revealed that, among patients who reported low fear at the end of an exposure session, those who had received DCS evidenced significantly greater clinical improvement at the next session, relative to those who had received placebo. In contrast, when exposure end fear was high, patients receiving DCS exhibited less clinical improvement at the following session than patients receiving placebo. Similarly, patients who had received DCS evidenced lower clinical severity at posttreatment, relative to patients who had received placebo, only when their average end fear for medication-augmented sessions had been in the low to moderate range. Finally, these moderating effects of exposure success as indexed by end fear were not better accounted for by within-session extinction. CONCLUSIONS: The efficacy of DCS for augmenting exposure-based CBT depends on the success of exposure sessions. These findings may help guide the development of an algorithm for the effective use of DCS for augmenting exposure-based CBT. TRIAL REGISTRY: http://www.ClinicalTrials.gov, ID# NCT00633984, http://www.clinicaltrials.gov/ct2/show/NCT00633984.
RCT Entities:
OBJECTIVE: The evidence for the efficacy of D-cycloserine (DCS) for augmenting cognitive behavioral therapy (CBT) for anxiety disorders has been mixed. Guided by preclinical research and initial findings from a small-scale study involving humans, we tested the hypothesis that DCS enhancement of exposure therapy would be specific to successful exposure sessions. METHOD: Medication-free adults with generalized social anxiety disorder (N = 145) received 50 mg of DCS or placebo 1 h before each of 5 exposure sessions that were part of a standardized 12-session group CBT protocol. Participants provided fear ratings at the beginning and just before the end of exposure exercises. Independent raters, blind to group assignment, administered the clinical global impression improvement and severity scales at each session and at posttreatment. RESULTS: Mixed-effects analyses revealed that, among patients who reported low fear at the end of an exposure session, those who had received DCS evidenced significantly greater clinical improvement at the next session, relative to those who had received placebo. In contrast, when exposure end fear was high, patients receiving DCS exhibited less clinical improvement at the following session than patients receiving placebo. Similarly, patients who had received DCS evidenced lower clinical severity at posttreatment, relative to patients who had received placebo, only when their average end fear for medication-augmented sessions had been in the low to moderate range. Finally, these moderating effects of exposure success as indexed by end fear were not better accounted for by within-session extinction. CONCLUSIONS: The efficacy of DCS for augmenting exposure-based CBT depends on the success of exposure sessions. These findings may help guide the development of an algorithm for the effective use of DCS for augmenting exposure-based CBT. TRIAL REGISTRY: http://www.ClinicalTrials.gov, ID# NCT00633984, http://www.clinicaltrials.gov/ct2/show/NCT00633984.
Authors: Stefan G Hofmann; Jasper A J Smits; Anu Asnaani; Cassidy A Gutner; Michael W Otto Journal: Pharmacol Biochem Behav Date: 2010-12-04 Impact factor: 3.533
Authors: Adam J Guastella; Rick Richardson; Peter F Lovibond; Ronald M Rapee; Jonathan E Gaston; Philip Mitchell; Mark R Dadds Journal: Biol Psychiatry Date: 2008-01-07 Impact factor: 13.382
Authors: Michael W Otto; David F Tolin; Naomi M Simon; Godfrey D Pearlson; Shawnee Basden; Suzanne A Meunier; Stefan G Hofmann; Katherine Eisenmenger; John H Krystal; Mark H Pollack Journal: Biol Psychiatry Date: 2009-10-06 Impact factor: 13.382
Authors: Eric A Storch; Lisa J Merlo; Michael Bengtson; Tanya K Murphy; Mark H Lewis; Mark C Yang; Marni L Jacob; Michael Larson; Adam Hirsh; Melanie Fernandez; Gary R Geffken; Wayne K Goodman Journal: Int Clin Psychopharmacol Date: 2007-07 Impact factor: 1.659
Authors: Matt G Kushner; Suck Won Kim; Christopher Donahue; Paul Thuras; David Adson; Michael Kotlyar; James McCabe; Jillian Peterson; Edna B Foa Journal: Biol Psychiatry Date: 2007-06-22 Impact factor: 13.382
Authors: Sabine Wilhelm; Ulrike Buhlmann; David F Tolin; Suzanne A Meunier; Godfrey D Pearlson; Hannah E Reese; Paul Cannistraro; Michael A Jenike; Scott L Rauch Journal: Am J Psychiatry Date: 2008-02-01 Impact factor: 18.112
Authors: Michael W Otto; M Alexandra Kredlow; Jasper A J Smits; Stefan G Hofmann; David F Tolin; Rianne A de Kleine; Agnes van Minnen; A Eden Evins; Mark H Pollack Journal: Biol Psychiatry Date: 2015-09-25 Impact factor: 13.382
Authors: Joseph F McGuire; Scott P Orr; Joey K-Y Essoe; James T McCracken; Eric A Storch; John Piacentini Journal: Expert Rev Neurother Date: 2016-06-27 Impact factor: 4.618
Authors: Michael W Otto; Gladys N Pachas; Corinne Cather; Susanne S Hoeppner; Samantha J Moshier; Bridget A Hearon; Heather Burrell Ward; Alexandra B Laffer; Jasper A J Smits; A Eden Evins Journal: Cogn Behav Ther Date: 2018-08-16
Authors: Alicia E Meuret; Thomas Ritz; Frank H Wilhelm; Walton T Roth; David Rosenfield Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2018-02-03
Authors: Jasper A J Smits; Brooke Y Kauffman; Eunjung Lee-Furman; Michael J Zvolensky; Michael W Otto; Megan E Piper; Mark B Powers; David Rosenfield Journal: Contemp Clin Trials Date: 2016-03-23 Impact factor: 2.226
Authors: Eric A Storch; Sabine Wilhelm; Susan Sprich; Aude Henin; Jamie Micco; Brent J Small; Joseph McGuire; P Jane Mutch; Adam B Lewin; Tanya K Murphy; Daniel A Geller Journal: JAMA Psychiatry Date: 2016-08-01 Impact factor: 21.596